Target intelligence / Profile preview

Succinate dehydrogenase complex subunit D (SDHD)

Target
SDHD
Molecular classification
Enzyme (respiratory chain enzyme subunit), Mitochondrial complex II subunit, Transmembrane protein
01

Overview

Succinate dehydrogenase complex subunit D (SDHD) is an integral membrane protein that forms part of succinate dehydrogenase (complex II) in the mitochondrial inner membrane. It is one of four subunits (along with SDHA, SDHB, and SDHC) and functions as an anchor, ensuring the complex is properly situated in the membrane. SDHD cooperates with other subunits to transfer electrons from succinate (via FAD and Fe-S clusters) to ubiquinone, linking the citric acid cycle and the electron transport chain for ATP production. Mutations in the SDHD gene disrupt mitochondrial energy metabolism and are strongly implicated in certain familial cancers, including paragangliomas, pheochromocytomas, and gastrointestinal stromal tumors. Functional loss of SDHD impairs succinate conversion, stabilizes HIF, and promotes tumorigenesis through altered oxygen sensing and metabolic signaling[1][2][3][4][5][6].

Other names
SDHDsuccinate dehydrogenase [ubiquinone] cytochrome b small subunitsuccinate dehydrogenase cytochrome b560 subunitcomplex II subunit D
02

Mechanism of action

Inhibition of SDH (complex II) enzymatic activity blocks electron flow, leading to accumulation of succinate, altered cellular metabolism, and induction of cell death or differentiation depending on context Inhibition alters cellular redox state and can promote hypoxia-inducible factor (HIF) stabilization

03

Biological functions

Electron transport in the mitochondrial respiratory chain (complex II)Citric acid (Krebs) cycle catalyst (succinate to fumarate conversion)ATP energy production via oxidative phosphorylationCellular oxygen sensing (succinate–HIF signaling)Tumor suppression
04

Disease associations

Cancer (notably paragangliomas, pheochromocytomas, gastrointestinal stromal tumors, and other SDH-deficient tumors)Mitochondrial disorders (rare)Other (hereditary paraganglioma–pheochromocytoma syndrome)
05

Safety considerations

Toxicity from broad SDH inhibition (impairs ATP production; leads to mitochondrial dysfunction in non-target tissues)Risk of lactic acidosis, neurotoxicity, cardiotoxicityLoss-of-function mutations in germline SDHD cause predisposition to tumors
06

Interacting drugs

Atpenin A5 (experimental, SDH inhibitor)

2 more in the full profile.

07

Biomarkers

Loss of SDHD/SDH complex immunostaining in tumor tissue (diagnostic for SDH-deficient tumors)Accumulation of succinate (metabolite marker)HIF stabilization markers (indirectly, in SDHD mutation contexts)

Beyond the preview

Go deeper on Succinate dehydrogenase complex subunit D (SDHD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Succinate dehydrogenase complex subunit D (SDHD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call